Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Gabapentin falls short in treating sickle cell pain

Key clinical point: Adding gabapentin to standard therapy did not significantly reduce vaso-occlusive pain in most patients with sickle cell disease enrolled in a phase 2 trial.

Major finding: The proportion of patients who experienced a greater than 33% decrease in pain from baseline to 3 hours posttreatment was 67% in the gabapentin arm and 59% in the placebo arm (P = .23).

Study details: A phase 2 trial of 86 evaluable patients.

Disclosures: The trial was sponsored by St. Jude Children’s Research Hospital in collaboration with Scan|Design Foundation. The speaker did not provide disclosure information at the meeting.

Citation:

Puri L et al. 2019 ASPHO Conference, Abstract 2011.